Los Angeles-based Kythera Biopharmaceuticals, which is developing products for the aesthetic medicine market, disclosed this morning that it has received $10M as part of the firm's Series C funding round. According to Kythera, the round included all of its existing investors, including Versant Ventures, ARCH Venture Partners, Prospect Venture Partners, BBT Capital Management/Apothecary Capital, JAFCO, PFM, and Altitude Life Science Ventures. The firm said that the round was part of a $40M, Series C financing round, which the firm had announced in 2008. Kythera said that the investment increases the firm's financial strength, and will go towards clinical development of its products.